Astria Therapeutics (ATXS) Competitors $5.16 +0.04 (+0.78%) As of 04/30/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ATXS vs. BGM, AUPH, ETNB, WVE, XFOR, ELVN, COLL, PHVS, SYRE, and MLYSShould you be buying Astria Therapeutics stock or one of its competitors? The main competitors of Astria Therapeutics include Qilian International Holding Group (BGM), Aurinia Pharmaceuticals (AUPH), 89bio (ETNB), Wave Life Sciences (WVE), X4 Pharmaceuticals (XFOR), Enliven Therapeutics (ELVN), Collegium Pharmaceutical (COLL), Pharvaris (PHVS), Spyre Therapeutics (SYRE), and Mineralys Therapeutics (MLYS). These companies are all part of the "pharmaceutical products" industry. Astria Therapeutics vs. Qilian International Holding Group Aurinia Pharmaceuticals 89bio Wave Life Sciences X4 Pharmaceuticals Enliven Therapeutics Collegium Pharmaceutical Pharvaris Spyre Therapeutics Mineralys Therapeutics Astria Therapeutics (NASDAQ:ATXS) and Qilian International Holding Group (NASDAQ:BGM) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, dividends, profitability, earnings, risk, analyst recommendations, community ranking, media sentiment and institutional ownership. Does the media prefer ATXS or BGM? In the previous week, Astria Therapeutics had 3 more articles in the media than Qilian International Holding Group. MarketBeat recorded 5 mentions for Astria Therapeutics and 2 mentions for Qilian International Holding Group. Astria Therapeutics' average media sentiment score of 1.72 beat Qilian International Holding Group's score of 0.93 indicating that Astria Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Astria Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Very Positive Qilian International Holding Group 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate ATXS or BGM? Astria Therapeutics presently has a consensus target price of $30.00, suggesting a potential upside of 481.40%. Given Astria Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Astria Therapeutics is more favorable than Qilian International Holding Group.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Astria Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 3 Strong Buy rating(s) 3.38Qilian International Holding Group 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has more volatility and risk, ATXS or BGM? Astria Therapeutics has a beta of 0.68, meaning that its share price is 32% less volatile than the S&P 500. Comparatively, Qilian International Holding Group has a beta of 1.32, meaning that its share price is 32% more volatile than the S&P 500. Is ATXS or BGM more profitable? Qilian International Holding Group's return on equity of 0.00% beat Astria Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Astria TherapeuticsN/A -43.58% -29.36% Qilian International Holding Group N/A N/A N/A Which has stronger valuation & earnings, ATXS or BGM? Qilian International Holding Group has higher revenue and earnings than Astria Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAstria TherapeuticsN/AN/A-$72.89M-$1.67-3.09Qilian International Holding Group$25.10M43.08-$1.44MN/AN/A Do insiders and institutionals hold more shares of ATXS or BGM? 99.0% of Astria Therapeutics shares are owned by institutional investors. 2.9% of Astria Therapeutics shares are owned by company insiders. Comparatively, 58.7% of Qilian International Holding Group shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Does the MarketBeat Community prefer ATXS or BGM? Astria Therapeutics received 574 more outperform votes than Qilian International Holding Group when rated by MarketBeat users. CompanyUnderperformOutperformAstria TherapeuticsOutperform Votes57473.21% Underperform Votes21026.79% Qilian International Holding GroupN/AN/A SummaryAstria Therapeutics beats Qilian International Holding Group on 8 of the 14 factors compared between the two stocks. Get Astria Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ATXS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ATXS vs. The Competition Export to ExcelMetricAstria TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$291.20M$6.89B$5.56B$7.83BDividend YieldN/A3.05%5.11%4.22%P/E Ratio-2.477.4422.4418.48Price / SalesN/A242.70393.95103.59Price / CashN/A65.8538.1834.62Price / Book1.556.516.774.25Net Income-$72.89M$143.21M$3.22B$248.23M7 Day Performance-0.96%1.98%1.45%0.89%1 Month Performance-4.44%6.89%3.96%3.53%1 Year Performance-45.68%-2.52%16.07%5.08% Astria Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ATXSAstria Therapeutics2.8114 of 5 stars$5.16+0.8%$30.00+481.4%-43.8%$291.20MN/A-2.4730Upcoming EarningsAnalyst ForecastNews CoverageBGMQilian International Holding GroupN/A$11.27+1.6%N/AN/A$1.10B$25.10M0.00298AUPHAurinia Pharmaceuticals2.633 of 5 stars$8.00-2.2%$11.50+43.8%+61.9%$1.09B$235.13M-53.33300Positive NewsETNB89bio2.7852 of 5 stars$7.40+6.6%$27.25+268.2%-5.8%$1.08BN/A-2.5440Upcoming EarningsPositive NewsWVEWave Life Sciences4.313 of 5 stars$6.83+1.5%$22.18+224.8%+56.6%$1.05B$108.30M-6.15240Upcoming EarningsAnalyst ForecastPositive NewsXFORX4 Pharmaceuticals3.8405 of 5 stars$5.34-6.3%$85.00+1,491.8%-87.2%$927.36M$2.56M-59.3380Stock SplitNews CoverageHigh Trading VolumeELVNEnliven Therapeutics2.2569 of 5 stars$18.91+3.8%$40.33+113.3%+8.9%$926.67MN/A-9.9550News CoveragePositive NewsGap DownCOLLCollegium Pharmaceutical4.051 of 5 stars$26.87+0.3%$43.60+62.3%-26.9%$904.19M$631.45M11.58210Upcoming EarningsPositive NewsPHVSPharvaris2.1943 of 5 stars$17.06+1.3%$42.67+150.1%-24.8%$892.07MN/A-6.0930Analyst ForecastGap DownHigh Trading VolumeSYRESpyre Therapeutics1.7938 of 5 stars$14.67+3.8%$49.57+237.9%-53.9%$884.25M$890,000.00-1.96100Upcoming EarningsPositive NewsMLYSMineralys Therapeutics2.3896 of 5 stars$13.56+1.6%$33.00+143.4%+16.0%$879.72MN/A-3.7328Upcoming EarningsShort Interest ↑ Related Companies and Tools Related Companies Qilian International Holding Group Competitors Aurinia Pharmaceuticals Competitors 89bio Competitors Wave Life Sciences Competitors X4 Pharmaceuticals Competitors Enliven Therapeutics Competitors Collegium Pharmaceutical Competitors Pharvaris Competitors Spyre Therapeutics Competitors Mineralys Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ATXS) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredThey rigged the gameThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | SponsoredIf you missed your chance with Tesla...Elon Musk is moments from launching a revolutionary technology some Silicon Valley insiders are calling "The F...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Astria Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Astria Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ATXS Stock Free ATXS Stock Alerts